Get started
Author

Chihiro Nakayama Kondoh

Observed names: C. Kondoh, C.N. Kondoh, CHIHIRO KONDOH, Chihiro Kondoh, Chihiro N Kondoh, Kondoh, Chihiro
Observed institutions: Institut Gustave Roussy, Juntendo University, National Cancer Centre Japan, Saitama Cancer Center, Japanese Red Cross Nagoya Daiichi Hospital, Aichi Cancer Center, National Cancer Center Hospital East, Toranomon Hospital, Aichi Cancer Center Hospital
ORCID: 0000-0001-6189-4851
Observed ORCID: 0000-0001-6189-4851
OpenAlex ID: A5075979601
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial
2022 · Chigusa Morizane, Nozomu Machida, et al. · JAMA Oncology · 128
PDF
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial
2020 · Hidetoshi Hayashi, Yuichi Takiguchi, et al. · JAMA Oncology · 113
PDF
Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study
2015 · Chihiro Kondoh, Kohei Shitara, et al. · BMC Palliative Care · 87
PDF
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
2019 · Momoko Takahashi, Yukinori Ozaki, et al. · BMC Cancer · 61
PDF
A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
2019 · Satoru Miura, Tateaki Naito, et al. · BMC Cancer · 58
PDF
Muscle wasting associated with the long-term use of mTOR inhibitors
2016 · Bishal Gyawali, Tomoya Shimokata, et al. · Molecular and Clinical Oncology · 52
PDF
Prognostic Impact of the 6th and 7th American Joint Committee on Cancer TNM Staging Systems on Esophageal Cancer Patients Treated With Chemoradiotherapy
2011 · Motoo Nomura, Kohei Shitara, et al. · International Journal of Radiation Oncology*Biology*Physics · 48
Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma
2013 · Shigenori Kadowaki, Yasushi Yatabe, et al. · Case Reports in Oncology · 47
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
2021 · Brian I. Rini, Michael B. Atkins, et al. · European Urology Oncology · 34
Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients
2020 · Yoshihiko Tomita, Katsunori Tatsugami, et al. · International Journal of Urology · 32
PDF
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
2019 · Takeshi Suzuki, Yasutaka Sukawa, et al. · Clinical Colorectal Cancer · 32
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
2021 · Satoshi Tamada, Chihiro Kondoh, et al. · International Journal of Clinical Oncology · 27
PDF
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
2017 · Yukinori Ozaki, Junichi Shindoh, et al. · BMC Cancer · 25
PDF
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
2022 · Hiromichi Nakajima, Kenichi Harano, et al. · The Breast · 24
PDF
Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain
2013 · Motoo Nomura, Koichi Inoue, et al. · Clinical Journal of Pain · 24
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
2018 · Chihiro Kondoh, Shigenori Kadowaki, et al. · Gastric Cancer · 18
PDF
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
2023 · Motoko Yanagita, Satoru Muto, et al. · Clinical and Experimental Nephrology · 16
PDF
Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation
2021 · Toru Mukohara, Ako Hosono, et al. · The Oncologist · 15
PDF
Recursive Partitioning Analysis for New Classification of Patients With Esophageal Cancer Treated by Chemoradiotherapy
2012 · Motoo Nomura, Kohei Shitara, et al. · International Journal of Radiation Oncology*Biology*Physics · 15
A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non‐Small Cell Lung Cancer (NEXTAC‐TWO)
2025 · Shuichi Mitsunaga, Tateaki Naito, et al. · Journal of Cachexia Sarcopenia and Muscle · 13
PDF
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial
2023 · Naoki Izawa, Toshiki Masuishi, et al. · Targeted Oncology · 13
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
2019 · Rika Kizawa, Yuji Miura, et al. · Journal of Clinical Oncology · 12
Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma
2017 · Yuji Miura, Naoko Inoshita, et al. · Urologic Oncology Seminars and Original Investigations · 12
Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study
2022 · Hisateru Yasui, Atsushi Takeno, et al. · International Journal of Colorectal Disease · 11
PDF
NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
2020 · Junko Tanizaki, Kan Yonemori, et al. · Journal of Clinical Oncology · 11
Works count: 114
Citation count: 1,078
H-index: 16
I10-index: 26
Year
Topic
Type